Hypertension Journal

Register      Login

Table of Content

2016 | July-September | Volume 2 | Issue 3

RESEARCH ARTICLE

Shawna D Nesbitt

Prehypertension: Does It Still Matter?

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:4] [Pages No:109 - 112]

   DOI: 10.5005/jp-journals-10043-0041  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Nesbitt SD. Prehypertension: Does It Still Matter? Hypertens J 2016;2(3):109-112.

RESEARCH ARTICLE

Amier Ahmad, Navin C Nanda

Echocardiographic Evaluation of Left Ventricular Systolic and Diastolic Function in Hypertension

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:5] [Pages No:113 - 117]

   DOI: 10.5005/jp-journals-10043-0042  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Ahmad A, Nanda NC. Echocardio-graphic Evaluation of Left Ventricular Systolic and Diastolic Function in Hypertension. Hypertens J 2016;2(3):113-117.

RESEARCH ARTICLE

Vijay Viswanathan, A Anitha Rani

Proteinuria in Nondiabetic Patients: Clinical Significance

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:6] [Pages No:118 - 123]

   DOI: 10.5005/jp-journals-10043-0043  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Viswanathan V, Rani AA. Proteinuria in Nondiabetic Patients: Clinical Significance. Hypertens J 2016;2(3):118-123.

RESEARCH ARTICLE

Meenakshi Chenniappan

Blood Pressure Variability: Assessment, Prognostic Significance, and Management

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:7] [Pages No:124 - 130]

   DOI: 10.5005/jp-journals-10043-0044  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Chenniappan M. Blood Pressure Variability: Assessment, Prognostic Significance, and Management. Hypertens J 2016;2(3):124-130.

RESEARCH ARTICLE

Mie Saiki, Vesna D Garovic

Hypertension and Pregnancy: Mechanisms and Management

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:8] [Pages No:131 - 138]

   DOI: 10.5005/jp-journals-10043-0045  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Saiki M, Garovic VD. Hypertension and Pregnancy: Mechanisms and Management. Hypertens J 2016;2(3):131-138.

RESEARCH ARTICLE

Gary E Sander, Camilo Fernandez, Philip J Kadowitz, Thomas D Giles

Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:6] [Pages No:139 - 144]

   DOI: 10.5005/jp-journals-10043-0046  |  Open Access |  How to cite  | 

Abstract

Aim

To provide a perspective on the effect of Sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular (CV) risk reduction in type 2 diabetes mellitus (DM) patients.

Background

Sodium-glucose co-transporter 2 inhibitors have been introduced as hypoglycemic agents for the treatment of type 2 diabetes by the unique mechanism of inhibiting the SGLT2 protein-mediated uptake of glucose by the kidney, producing an osmotic diuresis and some degree of natriuresis. The Food and Drug Administration (FDA) has thus far approved three drugs of this class for the treatment of type 2 diabetes – empagliflozin, canagliflozin, and dapagliflozin.

Review results

During the clinical trials performed to establish efficacy in diabetes control, these drugs were found to exert a range of beneficial effects beyond glucose lowering. The most interesting of these has been a reduction in systolic blood pressure (SBP) by an average of 3 to 5 mm Hg and diastolic blood pressure (DBP) of 2 to 3 mm Hg. A larger and even more unexpected discovery was that empagliflozin reduced the primary outcome of death from CV causes and nonfatal myocardial infarctions and strokes from 12.1% in the placebo group to 10.5% in an empagliflozin group in a clinical trial enrolling high CV risk patients. Overall, there was a 30 to 40% reduction in heart failure hospitalizations (HFHs) and all-cause deaths, with the event reduction appearing within the first 6 months and persisting to the trial conclusion.

Conclusion

The mechanisms for the aforementioned impressive beneficial events remain unclear, but may involve improvements in such parameters as blood pressure, vascular volume, myocardial glucose availability, reduced arterial vascular stiffness, and improvements in autonomic nervous system function. At this time, all approved SGLT2 inhibitors appear similar in pharmacological actions. Clinical trials are now in progress – or under development – that will further explore the CV actions and outcomes of these drugs.

Clinical significance

This review may aid to unify the existing knowledge on SGLT2 inhibitors and CV risk reduction, and set the path for further research endeavors to clarify mechanisms of action associated with additional CV benefits.

How to cite this article

Sander GE, Fernandez C, Kadowitz PJ, Giles TD. Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Hypertens J 2016;2(3):139-144.

RESEARCH ARTICLE

Pankaj Manoria, Prabhash C Manoria

Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:8] [Pages No:145 - 152]

   DOI: 10.5005/jp-journals-10043-0047  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Manoria PC, Manoria P, Mishra N. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertens J 2016;2(3):145-152.

RESEARCH ARTICLE

David A Calhoun

Clinical Perspective

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:7] [Pages No:153 - 159]

   DOI: 10.5005/jp-journals-10043-0048  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Calhoun DA. Clinical Perspective. Hypertens J 2016;2(3):153-159.

RESEARCH ARTICLE

Venkatesh K Raman, Vasilios Papademetriou

Revival of Renal Denervation Therapy for Hypertension: Real Hope or just a Dream?

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:9] [Pages No:160 - 168]

   DOI: 10.5005/jp-journals-10043-0049  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Raman VK, Papademetriou V. Revival of Renal Denervation Therapy for Hypertension: Real Hope or just a Dream? Hypertens J 2016;2(3):160-168.

RESEARCH ARTICLE

Debbie L Cohen

Device-based Therapies for Hypertension

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:9] [Pages No:169 - 177]

   DOI: 10.5005/jp-journals-10043-0050  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Cohen DL. Device-based Therapies for Hypertension. Hypertens J 2016;2(3):169-177.

RESEARCH ARTICLE

Kakarla Subbarao

Primary Aldosteronism

[Year:2016] [Month:July-September] [Volume:2] [Number:3] [Pages:2] [Pages No:178 - 179]

   DOI: 10.5005/jp-journals-10043-0051  |  Open Access |  How to cite  | 

Abstract

How to cite this article

Subbarao K. Primary Aldosteronism. Hypertens J 2016;2(3):178-179.

© Jaypee Brothers Medical Publishers (P) LTD.